mynth
03/2026Majority

Lone Star Funds takes majority stake in Lonza Chi

SWITZERLAND Life Sciences / Pharma & Biotech / CDMO EV CHF 1–10bn

Context

Lone Star Funds has entered into a definitive agreement to acquire a majority stake in Lonza Group’s Capsules & Health Ingredients (CHI) division. Lonza will retain a 40% equity position in the newly independent business, ensuring industrial continuity and shared upside in the future growth of the platform. The strategic rationale for Lonza is the completion of its long-term transformation into a "pure-play" CDMO (Contract Development and Manufacturing Organization). For CHI, the transition to a standalone entity under Lone Star’s control is designed to enhance its strategic agility and provide the dedicated capital necessary to accelerate innovation in plant-based capsules and nutritional ingredients. The sale process, which began in late 2024, was advised by Bank of America and Centerview Partners. This carve-out follows several other Lonza divestitures, including its Personalized Medicines and MODA software businesses.

By taking control of Lonza Chi, Lone Star Funds continues its expansion strategy. Previously, the group had completed 2 acquisitions, including SPX Flow in 2022.

Lonza Chi, which reported an EBITDA margin of [members only] in 2024, is valued in this transaction at an EV/EBITDA multiple of 5x–12x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Lonza CHI (Capsules & Health Ingredients) is a global leader in the production of hard capsules and dosage form solutions for the pharmaceutical and nutraceutical industries. The business operates across three integrated segments: Hard Empty Capsules (gelatin and plant-based), Dosage Form Solutions, and Health Ingredients (science-backed nutrition for joint health and energy). With a manufacturing footprint spanning the Americas, Europe, and Asia Pacific, CHI is recognized for its high-quality technical capabilities and established relationships with blue-chip global customers. The entity acts as a critical supply chain partner, offering end-to-end development platforms from raw ingredients to finished dosage forms, benefiting from structural growth trends in the global health and active lifestyle markets.

Ent. Value

CHF 1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

5x–12x

EV / EBIT

[members only]

Historical Financials (CHF)

Year
Rev
EBITDA
EBIT
2024
CHF 1–10bn
CHF 250–500M
[members only]
2023
CHF 1–10bn
CHF 250–500M
[members only]

Other operations with Lone Star Funds

Other operations with Lone Star Funds
DateAcquirerTargetCountrySector
04/2022LONE STAR FUNDSSPX FLOWUNITED STATESSpecial Machinery
07/2017LONE STAR FUNDSESMALGLASSSPAINSpecialty Chemicals

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
04/2026REVENIO GROUP CORPORATIONVISIONIX INTERNATIONALFRANCEDiagnostic Equipment
04/2026GILEAD SCIENCESARCELLXUNITED STATESR&D Biotech
03/2026SIPAREXWINNCAREFRANCEMedical Devices
03/2026ABBOTT LABORATORIESEXACT SCIENCESUNITED STATESDiagnostic Equipment
03/2026DEUTSCHE BETEILIGUNGS (DBAG)HIPP TECHNOLOGY GROUPGERMANYImplants & Prosthetics
03/2026RESONETICSRESOLUTION MEDICALUNITED STATESMedical Devices
02/2026VIVO CAPITALDUTSCHERFRANCEMedical Consumables
02/2026CIMGDAREN TECHNOLOGYCHINAR&D Biotech
02/2026IMA GROUPPROSYSIRELANDMedical Devices
02/2026NORD HOLDINGHALLMARQ VETERINARY IMAGINGUNITED KINGDOMDiagnostic Equipment

REFERENCES

Valuation range: EV CHF 1–10bn

Revenue range: CHF 1–10bn

EBITDA range: CHF 250–500M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 5x - 12x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Lonza Chi by Lone Star Funds are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Lonza Chi, a Swiss company specialised in Pharma & Biotech, by Lone Star Funds in 2026.

How was the acquisition of Lonza Chi by Lone Star Funds valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the CHF 1–10bn band, its EV/EBITDA multiple within the 5x - 12x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Lonza Chi’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Lonza Chi generated annual revenue estimated in the CHF 1–10bn range and EBITDA in the CHF 250–500M bracket (FY 2024). Detailed financial figures are available to members.

What sources support the information on this transaction?

The details of this transaction are sourced directly from the official corporate announcement published on the parties’ institutional website, ensuring primary-source verification of the closing and perimeter.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.